Maplight Therapeutics (NASDAQ:MPLT) Insider James Woodruff Lillie Sells 24,811 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 24,811 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36. Following the sale, the insider directly owned 243,450 shares in the company, valued at $7,001,622. The trade was a 9.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total transaction of $312,879.00.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The stock was sold at an average price of $27.96, for a total transaction of $441,795.96.

Maplight Therapeutics Price Performance

NASDAQ:MPLT opened at $29.04 on Thursday. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28. The business’s 50-day simple moving average is $22.60. The company has a market capitalization of $1.24 billion and a price-to-earnings ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($1.05) by ($1.42). As a group, analysts anticipate that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Strs Ohio purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $53,000. Bank of New York Mellon Corp increased its holdings in Maplight Therapeutics by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock valued at $802,000 after buying an additional 3,608 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Maplight Therapeutics during the fourth quarter valued at approximately $70,000. New York State Common Retirement Fund purchased a new stake in Maplight Therapeutics during the fourth quarter valued at approximately $93,000. Finally, MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics during the fourth quarter valued at approximately $172,000.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Wall Street Zen cut shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. TD Cowen assumed coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating for the company. Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: HC Wainwright opened/updated coverage and issued detailed quarterly and FY estimates alongside a Buy rating and a $45 price target (implies ~55% upside from the recent price); the report provides a near?term analyst catalyst and a bullish valuation anchor. HC Wainwright coverage (MarketBeat)
• Positive Sentiment: Needham reaffirmed its Buy rating on MPLT, reinforcing sell?side support that can sustain buying interest. Needham reaffirmation (The Globe and Mail)
• Neutral Sentiment: Morningstar quote/coverage appears in the tape (useful for tracking consensus/third?party data) but contains no new fundamental update by itself. Morningstar MPLT quote
• Negative Sentiment: Significant insider selling reported May 4–6: CEO Christopher Kroeger sold multiple blocks (~23,701 shares on May 6 and earlier sales), CFO Vishwas Setia, and insiders James W. Lillie and Erin P. Foff also sold material stakes. These transactions reduce insider holdings and may add near?term supply pressure, though each sale was made under pre?arranged Rule 10b5?1 plans (which weakens the signal that sales reflect new negative company information). See CEO Form 4 filing. CEO Form 4 (SEC)
• Negative Sentiment: Additional insider Form 4 filings for James W. Lillie and Erin P. Foff confirm multi?day sales at similar prices (May 4–6). Investors should monitor total sold vs. remaining insider ownership and trading volume to gauge impact. James W. Lillie Form 4 (SEC)

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.